Company: ISRG
Filing Date: 2025-07-23
Form Type: 10-Q
Source: 0001035267-25-000192
Chunk: 117

Company: INTUITIVE SURGICAL INC
Filing Date: 2025-07-23
Form: 10-Q
Item: Item 2
Chunk 117
---
 37 

41

Product Revenue

Three Months Ended June 30, 2025

Product revenue increased by 21% to $2.05 billion for the three months ended June 30, 2025, compared to $1.69 billion for the three months ended June 30, 2024.

Instruments and accessories revenue increased by 18% to $1.47 billion for the three months ended June 30, 2025, compared to $1.24 billion for the three months ended June 30, 2024. The increase in instruments and accessories revenue was primarily driven by approximately 17% higher da Vinci procedure volume, approximately 52% higher Ion procedure volume, and customer buying patterns. The second quarter 2025 U.S. da Vinci procedure growth was approximately 14%, driven primarily by strong growth in general surgery procedures, most notably cholecystectomy, hernia repair, and appendectomy procedures, as well as growth in gynecological procedures. The number of U.S. da Vinci bariatric procedures performed declined in the high-single digits in the second quarter of 2025 compared to the second quarter of 2024. The second quarter 2025 OUS da Vinci procedure growth was approximately 23%, driven by growth in general surgery procedures, most notably colorectal and hernia repair procedures, urologic procedures, most notably prostatectomy and partial nephrectomy procedures, and gynecologic procedures, most notably hysterectomy procedures. Geographically, the second quarter 2025 OUS da Vinci procedure growth was driven by several markets with particular strength in India and South Korea.

Systems revenue increased by 28% to $575 million for the three months ended June 30, 2025, compared to $448 million for the three months ended June 30, 2024. The higher second quarter 2025 system revenue was primarily driven by an increase in da Vinci system placements, higher operating lease revenue, and higher ASPs in the second quarter of 2025, driven by an increase in da Vinci 5 system placements.

During the second quarter of 2025, 395 da Vinci surgical systems were placed compared to 341 systems during the second quarter of 2024. By geography, 216 systems were placed in the U.S., 73 in Europe, 69 in Asia, and 37 in other markets during the second quarter of 2025, compared to 149 systems placed in the U.S., 71 in Europe,